Get Social With Us
 

BioProcessBlog

Trends and issues in biopharmaceutical development

A Closer Look at the Capacity Glut

Most recent analyses of the supply and demand for mammalian cell culture manufacturing capacity confirm a global excess. However, with only ten companies controlling almost 80% of this capacity, the apparent glut may not be as large as it seems. If we look separately at those companies with manufacturing capacity...

Read More

EMA Tackles Biosimilar MAbs

Following its trail-blazing issuance of guidelines for the approval of biosimilar well-characterized molecules such as insulin and human growth hormone, the EMA recently issued a draft guideline on biosimilar medicines containing monoclonal antibodies (MAbs).   Considering the complexity of MAbs, this brave step forward in the regulation of biosimilars is a welcome...

Read More